We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine.
Expertise
From patient-based disease models to novel therapeutic molecules.
Pipeline
Innovation holds the key. Our pipeline of drug discovery programs.
Partner with us
Initiate, codevelop or support our discovery programs.
Newsroom
Keep posted about
our latest developments
and achievements
Ksilink wishes you all the best for 2022!
What you see here is neither a virtual firework nor has Ksilink become an expressionist. We took this beautiful picture, figuring the AI-based analysis of the pharmacological...
The ANR supports our efforts in drug discovery for Myotonic Dystrophy type 1
Ksilink is happy to announce the initiation of the ANR funded project "Target-agnostic drug discovery approaches for neuromuscular diseases (TREAD)". This project is supporting...
New solutions to treat Rubinstein-Taybi
Ksilink is happy to have welcomed the team of Prof. Valérie Mezger-Lallemand from Université Didérot to initiate a collaboration with the aim to establish a new patient-based disease model to identify …
They trust us
“Patient-derived disease models used for phenotypic drug discovery purposes carry a huge potential. We strongly believe in Ksilink as a key player for effectively bridging the gap between scientific excellence and the pharma industry.”
Jacques Volckmann, Head of R&D, Sanofi, France
“Ksilink’s capacities to apply patient-derived disease models for high-throughput, high-content screening by using AI-driven deep learning computation is outstanding.”
Wolfram Zimmermann, CSO, Myriamed GmbH, Germany
“Bridging the gap between academic clinical research and industry is key to enable the precision medicine of tomorrow. We see big value in the ability of Ksilink to translate clinical expertise into treatment for diseases with high unmet medical need .”
Andreas Meyer-Lindenberg, Director and CEO, Central Institute of Mental Health, Germany
“Phenotypic screening using most authentic disease models is clearly paving the way towards next generation medicine. We strongly believe in Ksilink’s potential, allowing the generation of valuable first-in-class therapeutic molecules.”
Bert Klebl, Managing Director of Lead Discovery Center, Germany